Suppression of NF-κB and NF-κB regulated oxidative stress and neuroinflammation by BAY 11-7082 (IκB phosphorylation inhibitor) in experimental diabetic neuropathy

Biochimie

Volumn 94, Issue 5, 2012, Pages 1158-1165

  Kumar, Ashutosh ^a   Negi, Geeta ^a   Sharma, Shyam S ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Diabetic neuropathy; Inflammation; NF B; Oxidative stress

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CYCLOOXYGENASE 2; GLUTATHIONE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; STREPTOZOCIN; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE MODEL; ENZYME BLOOD LEVEL; LIPID PEROXIDATION; MALE; NERVE FUNCTION; NERVOUS SYSTEM INFLAMMATION; NOCICEPTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SCIATIC NERVE; SPRAGUE DAWLEY RAT;

ANIMALS; BLOTTING, WESTERN; DIABETIC NEUROPATHIES; GLUTATHIONE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERLEUKIN-6; MALE; MALONDIALDEHYDE; NF-KAPPA B; NITRILES; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SULFONES; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 84862786890     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2012.01.023     Document Type: Article

References (53)

1. J.L. Edwards, A.M. Vincent, H.T. Cheng, and E.L. Feldman Diabetic neuropathy: mechanisms to management Pharmacol. Ther. 120 2008 1 34
2. Y. Kuzumoto, S. Kusunoki, N. Kato, M. Kihara, and P.A. Low Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat Diabetologia 49 2006 3085 3093
3. F. Li, C. Szabo, P. Pacher, G.J. Southan, O.I. Abatan, T. Charniauskaya, M.J. Stevens, and I.G. Obrosova Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy Diabetologia 47 2004 710 717
4. Y. Zhao, W. Ye, K.S. Boye, J.H. Holcombe, J.A. Hall, and R. Swindle Prevalence of other diabetes-associated complications and comorbidities and its impact on health care charges among patients with diabetic neuropathy J. Diabetes Complications 24 2010 9 19
5. J.W. Russell, A. Berent-Spillson, A.M. Vincent, C.L. Freimann, K.A. Sullivan, and E.L. Feldman Oxidative injury and neuropathy in diabetes and impaired glucose tolerance Neurobiol. Dis. 30 2008 420 429
6. F. Li, O.I. Abatan, H. Kim, D. Burnett, D. Larkin, I.G. Obrosova, and M.J. Stevens Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats Neurobiol. Dis. 22 2006 669 676
7. N.E. Cameron, and M.A. Cotter Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway Curr. Drug Targets 9 2008 60 67
8. M.S. Hayden, and S. Ghosh Shared principles in NF-kappaB signaling Cell 132 2008 344 362
9. M. Karin, Y. Yamamoto, and Q.M. Wang The IKK NF-kappa B system: a treasure trove for drug development Nat. Rev. Drug Discov. 3 2004 17 26
10. C.C. Fraser Exploring the positive and negative consequences of NF-kappaB inhibition for the treatment of human disease Cell Cycle 5 2006 1160 1163
11. T. Ogihara, T. Asano, H. Katagiri, H. Sakoda, M. Anai, N. Shojima, H. Ono, M. Fujishiro, A. Kushiyama, Y. Fukushima, M. Kikuchi, N. Noguchi, H. Aburatani, Y. Gotoh, I. Komuro, and T. Fujita Oxidative stress induces insulin resistance by activating the nuclear factor-kappa B pathway and disrupting normal subcellular distribution of phosphatidylinositol 3-kinase Diabetologia 47 2004 794 805
12. E. Krishnan Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout Rheumatology (Oxford) 49 2010 1229 1238
13. S.E. Lakhan, A. Kirchgessner, and M. Hofer Inflammatory mechanisms in ischemic stroke: therapeutic approaches J. Transl Med. 7 2009 97
14. H. Vlassara, M. Torreggiani, J.B. Post, F. Zheng, J. Uribarri, and G.E. Striker Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging Kidney Int. Suppl. 2009 S3 11
15. A. Kumar, and S.S. Sharma NF-kappaB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy Biochem. Biophys. Res. Commun. 394 2010 360 365
16. N. Wakabayashi, S.L. Slocum, J.J. Skoko, S. Shin, and T.W. Kensler When NRF2 talks, who's listening? Antioxid. Redox Signal. 13 2010 1649 1663
17. N.G. Innamorato, A.I. Rojo, A.J. Garcia-Yague, M. Yamamoto, M.L. de Ceballos, and A. Cuadrado The transcription factor Nrf2 is a therapeutic target against brain inflammation J. Immunol. 181 2008 680 689
18. G.H. Liu, J. Qu, and X. Shen NF-kappaB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK Biochim. Biophys. Acta 1783 2008 713 727
19. E.D. Foehr, X. Lin, A. O'Mahony, R. Geleziunas, R.A. Bradshaw, and W.C. Greene NF-kappa B signaling promotes both cell survival and neurite process formation in nerve growth factor-stimulated PC12 cells J. Neurosci. 20 2000 7556 7563
20. A. Kumar, Y. Takada, A.M. Boriek, and B.B. Aggarwal Nuclear factor-kappaB: its role in health and disease J. Mol. Med. 82 2004 434 448
21. C.K. Glass, K. Saijo, B. Winner, M.C. Marchetto, and F.H. Gage Mechanisms underlying inflammation in neurodegeneration Cell 140 2010 918 934
22. R.L. Mosley, E.J. Benner, I. Kadiu, M. Thomas, M.D. Boska, K. Hasan, C. Laurie, and H.E. Gendelman Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's disease Clin. Neurosci. Res. 6 2006 261 281
23. T.D. Purves, and D.R. Tomlinson Diminished transcription factor survival signals in dorsal root ganglia in rats with streptozotocin-induced diabetes Ann. N. Y Acad. Sci. 973 2002 472 476
24. Y. Wang, A.M. Schmeichel, H. Iida, J.D. Schmelzer, and P.A. Low Enhanced inflammatory response via activation of NF-kappaB in acute experimental diabetic neuropathy subjected to ischemia-reperfusion injury J. Neurol. Sci. 247 2006 47 52
25. N. Kawamura, P.J. Dyck, A.M. Schmeichel, J.K. Engelstad, P.A. Low, and P.J. Dyck Inflammatory mediators in diabetic and non-diabetic lumbosacral radiculoplexus neuropathy Acta Neuropathol. 115 2008 231 239
26. A. Bierhaus, K.M. Haslbeck, P.M. Humpert, B. Liliensiek, T. Dehmer, M. Morcos, A.A. Sayed, M. Andrassy, S. Schiekofer, J.G. Schneider, J.B. Schulz, D. Heuss, B. Neundorfer, S. Dierl, J. Huber, H. Tritschler, A.M. Schmidt, M. Schwaninger, H.U. Haering, E. Schleicher, M. Kasper, D.M. Stern, B. Arnold, and P.P. Nawroth Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily J. Clin. Invest. 114 2004 1741 1751
27. M. Arora, A. Kumar, R.K. Kaundal, and S.S. Sharma Amelioration of neurological and biochemical deficits by peroxynitrite decomposition catalysts in experimenatal diabeic neuropathy Eur. J. Pharmacol. 596 2008 77 83
28. S.S. Sharma, A. Kumar, M. Arora, and R.K. Kaundal Neuroprotective potential of combination of resveratrol and 4-amino 1,8 naphthalimide in experimental diabetic neuropathy: focus on functional, sensorimotor and biochemical changes Free Radic. Res. 43 2009 400 408
29. S.S. Sharma, A. Kumar, and R.K. Kaundal Protective effects of 4-amino1,8-napthalimide, a poly (ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy Life Sci. 82 2008 570 576
30. S.S. Sharma, and S.G. Sayyed Effects of trolox on nerve dysfunction, thermal hyperalgesia and oxidative stress in experimental diabetic neuropathy Clin. Exp. Pharmacol. Physiol. 33 2006 1022 1028
31. G. Negi, A. Kumar, R.K. Kaundal, A. Gulati, and S.S. Sharma Functional and biochemical evidence indicating beneficial effect of melatonin and nicotinamide alone and in combination in experimental diabetic neuropathy Neuropharmacology 58 2010 585 592
32. G. Negi, A. Kumar, and S.S. Sharma Concurrent targeting of nitrosative stress-PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy Biochem. Biophys. Res. Commun. 391 2010 102 106
33. H. Ohkawa, N. Ohishi, and K. Yagi Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction Anal. Biochem. 95 1979 351 358
34. M.S. Moron, J.W. Depierre, and B. Mannervik Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver Biochim. Biophys. Acta 582 1979 67 78
35. G. Negi, A. Kumar, and S.S. Sharma Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-κB and Nrf2 cascades J. Pineal Res. 50 2011 124 131
36. I.G. Obrosova, V.R. Drel, C.L. Oltman, N. Mashtalir, J. Tibrewala, J.T. Groves, and M.A. Yorek Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats Am. J. Physiol. Endocrinol. Metab. 293 2007 E1645 E1655
37. A.M. Vincent, J.W. Russell, P. Low, and E.L. Feldman Oxidative stress in the pathogenesis of diabetic neuropathy Endocr. Rev. 25 2004 612 628
38. A.M. Vincent, J.L. Edwards, M. Sadidi, and E.L. Feldman The antioxidant response as a drug target in diabetic neuropathy Curr. Drug Targets 9 2008 94 100
39. L.E. Rojo, J.A. Fernandez, A.A. Maccioni, J.M. Jimenez, and R.B. Maccioni Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease Arch. Med. Res. 39 2008 1 16
40. F. Garcia Soriano, L. Virag, P. Jagtap, E. Szabo, J.G. Mabley, L. Liaudet, A. Marton, D.G. Hoyt, K.G. Murthy, A.L. Salzman, G.J. Southan, and C. Szabo Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation Nat. Med. 7 2001 108 113
41. A.M. Vincent, and E.L. Feldman New insights into the mechanisms of diabetic neuropathy Rev. Endocr. Metab. Disord. 5 2004 227 236
42. A.I. Vinik, and A. Mehrabyan Diabetic neuropathies Med. Clin. North Am. 88 2004 947 999 (xi)
43. M.S. Hayden, and S. Ghosh Signaling to NF-kappaB Genes Dev. 18 2004 2195 2224
44. R.S. Hundal, K.F. Petersen, A.B. Mayerson, P.S. Randhawa, S. Inzucchi, S.E. Shoelson, and G.I. Shulman Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes J. Clin. Invest. 109 2002 1321 1326
45. J.K. Kim, Y.J. Kim, J.J. Fillmore, Y. Chen, I. Moore, J. Lee, M. Yuan, Z.W. Li, M. Karin, P. Perret, S.E. Shoelson, and G.I. Shulman Prevention of fat-induced insulin resistance by salicylate J. Clin. Invest. 108 2001 437 446
46. W.A. Verri Jr., T.M. Cunha, C.A. Parada, S. Poole, F.Q. Cunha, and S.H. Ferreira Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development? Pharmacol. Ther. 112 2006 116 138
47. W.R. Coward, Y. Okayama, H. Sagara, S.J. Wilson, S.T. Holgate, and M.K. Church NF-kappa B and TNF-alpha: a positive autocrine loop in human lung mast cells? J. Immunol. 169 2002 5287 5293
48. J. Nam, B.D. Aguda, B. Rath, and S. Agarwal Biomechanical thresholds regulate inflammation through the NF-kappaB pathway: experiments and modeling PLoS One 4 2009 e5262
49. C. Juliana, T. Fernandes-Alnemri, J. Wu, P. Datta, L. Solorzano, J.W. Yu, R. Meng, A.A. Quong, E. Latz, C.P. Scott, and E.S. Alnemri Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome J. Biol. Chem. 285 2010 9792 9802
50. M. Kitazawa, Y. Shibata, S. Hashimoto, Y. Ohizumi, and T. Yamakuni Proinsulin C-peptide stimulates a PKC/IkappaB/NF-kappaB signaling pathway to activate COX-2 gene transcription in Swiss 3T3 fibroblasts J. Biochem. 139 2006 1083 1088
51. M. Bujalska, J. Tatarkiewicz, A. de Corde, and S.W. Gumulka Effect of cyclooxygenase and nitric oxide synthase inhibitors on streptozotocin-induced hyperalgesia in rats Pharmacology 81 2008 151 157
52. S.F. Kim, D.A. Huri, and S.H. Snyder Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2 Science 310 2005 1966 1970
53. K.J. Min, J.T. Lee, E.H. Joe, and T.K. Kwon An IkappaBalpha phosphorylation inhibitor induces heme oxygenase-1(HO-1) expression through the activation of reactive oxygen species (ROS)-Nrf2-ARE signaling and ROS-PI3K/Akt signaling in an NF-kappaB-independent mechanism Cell Signal. 23 2011 1505 1513